Adagene - Ads Each Representing 1.25 (ADAG) closed at $1.71 on November 13, 2026, down 14.5% from the previous close, on volume of 149,965 shares (30-day average 279,141).
Data as of November 13, 2026.
Globe Newswire (Mon, 9-Nov 7:00 AM ET)
Globe Newswire (Wed, 28-Oct 7:00 AM ET)
Adagene to Participate in the Guggenheim Securities 3rd Annual Healthcare Innovation Conference
Globe Newswire (Tue, 27-Oct 7:00 AM ET)
Adagene to Participate in H.C. Wainwright 4th Annual Immune Cell Engager Virtual Conference
Globe Newswire (Wed, 14-Oct 8:00 AM ET)
Globe Newswire (Tue, 22-Sep 8:00 AM ET)
Globe Newswire (Thu, 10-Sep 8:00 AM ET)
Globe Newswire (Wed, 9-Sep 8:00 AM ET)
Adagene to Participate in Three Upcoming Investor Conferences
Globe Newswire (Thu, 20-Aug 8:00 AM ET)
Adagene's $74.5M Cash Reserves Pave Way for 2026 Clinical Milestones and New Collaborations
Market Chameleon (Fri, 23-Jan 6:49 AM ET)
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.
Adagene - Ads Each Representing 1.25 trades on the NASDAQ stock market under the symbol ADAG.
As of November 13, 2026, ADAG stock price declined to $1.71 with 149,965 million shares trading.
ADAG has a beta of 0.72, meaning it tends to be less sensitive to market movements. ADAG has a correlation of 0.01 to the broad based SPY ETF.
ADAG has a market cap of $112.98 million. This is considered a Micro Cap stock.
In the last 3 years, ADAG traded as high as $4.85 and as low as $1.30.
The top ETF exchange traded funds that ADAG belongs to (by Net Assets): PGJ, EWX.
ADAG has underperformed the market in the last year with a price return of -5.0% while the SPY ETF gained +13.4%. ADAG has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -54.0% and -31.9%, respectively, while the SPY returned -2.8% and -0.2%, respectively.
ADAG support price is $1.81 and resistance is $2.19 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ADAG shares will trade within this expected range on the day.
